- End-to-end ownership of key clinical projects, from defining the clinical question, to data collection and cleaning, to publications as lead author.
- Generate clinically meaningful insights that support clinical adoption, regulatory submissions, reimbursement and guideline inclusion.
- Present findings at international conferences, and represent StratifAI in discussions with clinical and research partners.
- Identify evidence gaps and design studies to address them. Develop research questions, protocols and analysis plans together with an interdisciplinary team.
- Support existing scientific collaborations, identify new opportunities and prepare research proposals and applications for access to real-world and clinical-trial data.
Translational Scientist
Berlin - Hybrid
Full-time
Fixed-term
90,000 - 120,000 € per year
Your mission
Your profile
- A PhD, MD or equivalent qualification in computational biology, biomedical engineering, oncology, cancer biology or a related discipline, with a deep understanding of medical statistics.
- Demonstrated expertise in cancer biology, and an understanding of clinical guidelines on how existing biomarkers inform treatment decisions.
- Experience designing and executing statistical analysis protocols for clinical studies involving biomarkers, ideally in computational pathology.
- Strong Python skills and a core understanding of deep learning.
- A track record of first or last authored peer-reviewed publications and presentations at oncology journals/conferences.
Why us?
- The opportunity to build the evidence for novel AI biomarkers that are used in the real world, that could make a meaningful difference to cancer patients.
- Ownership of clinical projects from the initial question to publication and subsequent implications on product development.
- Fully covered frequent travels to the major oncology conferences around the world.
- Highly competitive salary.
- Equity to share in the company's success.
- Direct collaboration with the founders, an interdisciplinary team, and a scientific advisory board of world-class oncologists and key opinion leaders.
- Office space in the heart of Berlin.
About us
StratifAI is an innovative precision oncology startup developing the next generation of multimodal AI-based cancer biomarkers, with offices in Berlin and New York. Our products are developed with data that is collected in routine patient care, such as histology slides, clinical variables, and longitudinal outcome data. This enables us to develop and provide our biomarkers at scale, allowing cancer patients globally to receive the right treatment at the right time. Our first product, Polaris™ Breast, assesses the risk of distant metastasis at 5- and 10-years for patients with early breast cancer and is expected to be available for clinical use in Q1 2027 on the US as laboratory-developed test.